Synthetic Biologics, Inc. (SYN)
| Market Cap | 71.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.56M |
| Shares Out | 19.01M |
| EPS (ttm) | -0.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $0.550 |
| Previous Close | $0.580 |
| Change ($) | -0.030 |
| Change (%) | -5.19% |
| Day's Open | 0.523 |
| Day's Range | 0.460 - 0.580 |
| Day's Volume | 17,949,823 |
| 52-Week Range | 0.252 - 1.700 |
Synthetic Biologics (SYN) stock is soaring higher on heavy trading Tuesday even without a lack of news concerning the company. The post Synthetic Biologics: 6 Things for SYN Stock Investors to...
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2020 Results - Earnings Call Transcript
Synthetic Biologics' (SYN) CEO Steven Shallcross on Q2 2020 Results - Earnings Call Transcript
Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2020 Results - Earnings Call Transcript
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q4 2019 Results - Earnings Call Transcript
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q3 2019 Results - Earnings Call Transcript
Synthetic Biologics, Inc (SYN) CEO Steven Shallcross on Q2 2019 Results - Earnings Call Transcript
Synthetic Biologics' (SYN) CEO Steven Shallcross on Q1 2019 Results - Earnings Call Transcript
About SYN
Synthetic Biologics, a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transpla... [Read more...]
| Industry Biotechnology | IPO Date Jun 26, 2006 |
| CEO Steven Shallcross | Employees 11 |
| Stock Exchange NYSEAMERICAN | Ticker Symbol SYN |
Analyst Forecasts
According to 2 analysts, the average rating for SYN stock is "Buy." The 12-month stock price forecast is 1.25, which is an increase of 127.27% from the latest price.